NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA.
Details for the ASH 2024 presentation are as follows:
| Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide |
| Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center |
| Abstract #: 4823 |
| Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III |
| Date and Time: Monday, December 9, 2024, 6:00 PM - 8:00 PM PDT |
The abstract will be available online and can be accessed via the conference websites at ASH Annual Meeting Abstracts. Reprints of the poster will also be accessible on the Events & Presentations page of IN8bio’s website following the presentations.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogenic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit www.IN8bio.com.
Investors & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
This email address is being protected from spambots. You need JavaScript enabled to view it.
Patrick McCall
IN8bio, Inc.
646.933.5603
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.32 |
| Daily Change: | 0.005 1.58 |
| Daily Volume: | 129,558 |
| Market Cap: | US$15.070M |
November 12, 2024 November 12, 2024 August 08, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
